Azelaic Acid Exhibits Dual Antimicrobial and Quorum Sensing Inhibitory Activities Against Pathogens: In Vitro Evaluation and Molecular Docking Insights

This study demonstrates for the first time that azelaic acid functions as a dual antimicrobial and quorum sensing inhibitor against various pathogens, significantly attenuating virulence factors in *Pseudomonas aeruginosa* through dose-dependent mechanisms and molecular interactions with key regulatory proteins without directly inhibiting bacterial growth.

The Gist

The Big Problem: The "Superbug" Alarm

Imagine bacteria are like a criminal gang. For years, we've tried to stop them by shooting them with antibiotics (the "guns"). But the gang has learned to wear bulletproof vests. They are becoming "superbugs" (antimicrobial resistance), and our guns are no longer working. If we keep trying to kill them, they just get stronger and smarter.

The New Strategy: Disarming the Gang

Instead of trying to kill the bacteria, this study asks: What if we just took away their weapons and stopped them from talking to each other?

This is called Quorum Sensing (QS). Think of bacteria as a team of soldiers. They can't do much damage alone. But when they gather in a big group, they hold a "meeting" using chemical signals (like walkie-talkies) to say, "Okay, we are big enough now. Everyone, attack the host at the same time!"

This study tested a common, safe molecule called Azelaic Acid (AzA)—the same stuff found in many acne creams—to see if it could jam their walkie-talkies and stop them from attacking.

The Experiment: Testing the "Jammer"

The researchers tested AzA on a scary list of bacteria, including:

• Reference strains: The "standard" versions of bacteria found in labs.
• Clinical isolates: Real, nasty bacteria taken from sick patients, including some that are resistant to almost all drugs (MDR and PDR strains).

They did two main things:

1. Did it kill them? They checked if AzA stopped the bacteria from growing.
2. Did it silence them? They checked if AzA stopped the bacteria from producing "weapons" (virulence factors) like:
   • Pyocyanin: A toxic blue-green poison.
   • Elastase & Protease: Enzymes that chew up human tissue.
   • Alginate: A slimy slime (biofilm) that protects the bacteria.

The Results: A Double Victory

The results were surprisingly good.

1. The "Jammer" Worked Perfectly
Even at low doses where the bacteria were still alive and growing, AzA completely shut down their ability to coordinate an attack.

• The Analogy: Imagine a gang of thieves planning a bank heist. Usually, they wait until they have 50 members to strike. AzA didn't arrest them; it just stole their walkie-talkies. So, even though the thieves were still there, they couldn't agree on when to attack. They just stood around confused, unable to use their weapons.
• The Numbers: In many cases, AzA stopped the production of these "weapons" by over 90%. For example, it stopped the bacteria from making the tissue-eating enzymes almost entirely.

2. It Worked on the "Superbugs" Too
Even the bacteria that are resistant to almost every other drug (the PDR and MDR strains) fell silent when AzA was added. This is huge because it means AzA attacks a different part of the bacteria that the usual drugs can't touch.

3. The "Why": A Molecular Lock and Key
The researchers used computer simulations (molecular docking) to see how AzA works.

• The Analogy: Think of the bacteria's communication system as a giant lock. The bacteria have a specific key (a chemical signal) that fits into the lock to open the "attack" door.
• The Discovery: AzA acts like a piece of gum stuck in the lock. It doesn't fit perfectly like the real key, but it jams the mechanism enough so the real key can't turn. It sticks to the "locks" (proteins like LasR and PqsR) that the bacteria use to talk, confusing the system and preventing the attack order from being sent.

Why This Matters

• Safety: Azelaic acid is already used on human skin for acne. We know it's safe.
• No Resistance: Because AzA doesn't try to kill the bacteria, the bacteria have less reason to evolve and fight back. It's like disarming a criminal rather than shooting them; they don't need to build a bigger gun to survive.
• New Hope: This suggests we could use AzA (or similar drugs) alongside traditional antibiotics. The antibiotics kill the weak bacteria, while AzA keeps the strong ones from organizing a counter-attack.

The Bottom Line

This study is the first to show that Azelaic Acid is not just a skin cream ingredient, but a potential "silencer" for dangerous bacteria. It proves that we can fight superbugs by disarming them rather than just trying to kill them, offering a fresh, clever strategy in the war against antibiotic resistance.

Technical Summary

1. Problem Statement

The global rise of Antimicrobial Resistance (AMR) poses a critical threat to public health, with projections suggesting AMR could become the leading cause of death by 2050. Traditional antibiotics exert strong selective pressure, accelerating the evolution of resistance.

• Target Pathogens: The study focuses on Pseudomonas aeruginosa (a major cause of nosocomial infections, particularly in cystic fibrosis and immunocompromised patients), Staphylococcus aureus (including MRSA), and Enterobacteriaceae (e.g., E. coli, K. pneumoniae).
• Mechanism of Virulence: P. aeruginosa utilizes Quorum Sensing (QS)—a cell-to-cell communication system involving the Las, Rhl, and Pqs pathways—to coordinate the expression of virulence factors (e.g., pyocyanin, elastase, alginate, proteases) and biofilm formation.
• Therapeutic Gap: There is an urgent need for antivirulence strategies (specifically Quorum Sensing Inhibitors or QSIs) that disarm pathogens without killing them, thereby reducing selective pressure and the likelihood of resistance development.
• Knowledge Gap: While Azelaic Acid (AzA) is a known antimicrobial used in dermatology, its potential as a QS inhibitor in Gram-negative pathogens had not been previously characterized.

2. Methodology

The study employed a combination of in vitro biological assays and in silico molecular modeling.

A. Biological Evaluation (In Vitro)

• Strains Tested: Seven reference strains (P. aeruginosa PAO1, PA14, ATCC 27853; E. coli ATCC 25922; S. aureus ATCC 43300/6538; K. pneumoniae ATCC 33495; P. mirabilis ATCC 43091) and four clinical isolates (including MDR and PDR P. aeruginosa, ESBL E. coli, and clinical S. aureus).
• MIC Determination: Minimum Inhibitory Concentration (MIC) was determined via broth microdilution (CLSI standards) to establish bactericidal limits.
• Antivirulence Assays: Sub-inhibitory concentrations of AzA (250, 500, and 750 µg/mL) were applied to P. aeruginosa strains to assess the inhibition of QS-regulated virulence factors:
  • Pyocyanin: Extracted with chloroform and quantified via absorbance at 520 nm.
  • Protease: Measured using a protease reagent and absorbance at 595 nm.
  • Alginate: Precipitated with ethanol and quantified via carbazole assay at 530 nm.
  • Elastase: Measured using elastin-Congo red degradation and absorbance at 495 nm.
• Statistical Analysis: ANOVA and Tukey HSD tests were used to validate dose-dependency and significance ($p < 0.001$).

B. Computational Analysis (In Silico)

• Molecular Docking: Performed using AutoDock Vina 1.1.2.
• Targets: Key QS proteins were selected from the Protein Data Bank (PDB):
  • LasI (PDB: 1RO5): Autoinducer synthase.
  • LasR (PDB: 3IX3, 2UV0): Autoinducer receptor.
  • PqsD (PDB: 3H76): Enzyme in the PQS pathway.
  • PqsR (PDB: 4JVI): PQS receptor.
• Ligand Preparation: AzA was modeled in its dianionic form (physiological pH 7.4) and optimized using the MMFF94 force field.
• Validation: Protocols were validated by redocking native ligands (RMSD $\le$ 2.0 Å) and using positive controls (e.g., TZD-C8 for LasI). Interactions were analyzed using PLIP and Discovery Studio.

3. Key Contributions

1. First Report of AzA as a QSI: This is the first study to characterize Azelaic Acid as a Quorum Sensing Inhibitor specifically against P. aeruginosa.
2. Dual-Action Mechanism: The study demonstrates that AzA acts as a "dual-action" agent: it possesses antimicrobial properties (MICs) but, more importantly, exhibits potent antivirulence activity at sub-inhibitory concentrations.
3. Multitarget Modulation: Through molecular docking, the study proposes that AzA interacts with multiple nodes of the QS network (LasI, LasR, PqsD, PqsR), suggesting a multitarget modulatory mechanism rather than a single-target inhibition.
4. Clinical Relevance: The efficacy of AzA was validated against Multidrug-Resistant (MDR) and Pan-Drug-Resistant (PDR) clinical isolates, indicating its potential utility against "superbugs" where conventional antibiotics fail.

4. Key Results

A. Antimicrobial Susceptibility (MIC)

• MIC Values: Ranged from 250 to 1000 µg/mL.
  • P. aeruginosa (Reference & Clinical): 1000 µg/mL.
  • E. coli (Clinical) & S. aureus (Clinical): 250 µg/mL.
• Sub-inhibitory Strategy: Concentrations of 250, 500, and 750 µg/mL were used for virulence assays to ensure observed effects were due to virulence attenuation, not bacterial death.

B. Inhibition of Virulence Factors (P. aeruginosa)
AzA showed a dose-dependent inhibition of all tested virulence factors across reference and clinical strains ($p < 0.001$):

• Protease: The most sensitive factor. Inhibition reached >99% in reference strains (e.g., PA14 at 750 µg/mL) and significant reductions (up to 79%) in clinical isolates.
• Pyocyanin: Inhibition ranged from 13% to 98% (PA14 and PA Bro strains showed >97% inhibition at 750 µg/mL).
• Alginate: Inhibition reached 91% in the PA01 reference strain and ~72% in the PDR clinical isolate.
• Elastase: Showed moderate resilience but still achieved up to 80% inhibition in the PDR clinical isolate at the highest dose.

C. Molecular Docking Insights
AzA demonstrated moderate binding affinities (−5.3 to −6.5 kcal/mol) and stable interactions within conserved ligand-binding domains:

• LasI: Formed H-bonds with Ala106/Ile107 and hydrophobic contacts with Trp69/Phe105.
• LasR: Interacted with conserved residues (Tyr64, Thr75, Ser129) and formed a salt bridge with Arg61, mimicking the binding mode of native autoinducers.
• PqsD: The dianionic AzA formed a salt bridge with His257 and H-bonds with Cys112 (part of the catalytic triad), suggesting potential interference with substrate processing.
• PqsR: Occupied the hydrophobic cavity, interacting with Gln194 and Ile236.

5. Significance and Conclusion

• Therapeutic Potential: Azelaic Acid represents a promising candidate for drug repurposing. As an FDA-approved dermatological agent with a known safety profile, it could accelerate the transition to clinical trials for systemic or topical anti-infective therapies.
• Resistance Mitigation: By targeting virulence rather than viability, AzA exerts less selective pressure on bacteria, potentially slowing the development of resistance compared to traditional bactericidal antibiotics.
• Mechanistic Insight: The study provides a structural basis for AzA's activity, suggesting it acts as a multitarget modulator of the interconnected Las and PQS signaling pathways.
• Future Directions: While in vitro and in silico data are robust, the authors recommend further in vivo studies and clinical trials to validate the therapeutic efficacy of AzA as an antivirulence agent against MDR/PDR pathogens.

In summary, this paper establishes Azelaic Acid not just as an antimicrobial, but as a potent Quorum Sensing Inhibitor capable of disarming highly resistant P. aeruginosa strains, offering a novel strategy in the fight against antimicrobial resistance.